Lytix Biopharma

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Less than 1K followers

Lytix Biopharma is a biotechnology company in the clinical stage that develops new cancer immunotherapies. The company's technology is based on research in antimicrobial peptides, a defense aimed at pathogens. Lytix Biopharma's main product, LTX-315, is an oncolytic peptide for the purpose of personalizing immunotherapy. The company conducts its research and operations in Oslo.

Market cap

-

Turnover

-

Revenue

3.99M

EBIT %

-2,428.07 %

P/E

-

Dividend yield-%

-

Financial calendar

13.2

2025

Annual report '24

29.4

2025

General meeting '25

15.5

2025

Interim report Q1'25

ShowingAll content types

Regulatory press release1/22/2025, 7:05 AM

Lytix Biopharma AS - Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference

Lytix Biopharma

Regulatory press release1/15/2025, 3:01 PM

Lytix Biopharma AS - New share capital registered

Lytix Biopharma

Regulatory press release1/7/2025, 6:18 PM

Lytix Biopharma AS - Cancellation of Subsequent Offering

Lytix Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release1/2/2025, 10:45 AM

LYTIX: Financial calendar

Lytix Biopharma

Regulatory press release12/23/2024, 4:26 PM

Lytix Biopharma AS - New share capital registered

Lytix Biopharma

Regulatory press release12/17/2024, 7:05 AM

Lytix Biopharma AS: Key information relating to potential subsequent offering

Lytix Biopharma

Regulatory press release12/17/2024, 7:05 AM

Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates

Lytix Biopharma

Regulatory press release12/16/2024, 11:30 PM

Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed

Lytix Biopharma

Regulatory press release12/16/2024, 4:09 PM

Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Lytix Biopharma

Regulatory press release12/16/2024, 4:04 PM

Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid

Lytix Biopharma

Regulatory press release12/16/2024, 3:45 PM

Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Lytix Biopharma

Regulatory press release11/21/2024, 2:48 PM

Lytix Biopharma AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Lytix Biopharma

Press release11/20/2024, 9:35 AM

Redeye: Lytix Q3 2024 - First Patient in NeoLIPA

Lytix Biopharma

Regulatory press release11/19/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Lytix Biopharma

Regulatory press release11/12/2024, 9:33 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation

Lytix Biopharma

Press release11/6/2024, 9:23 PM

Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma

Lytix Biopharma

Regulatory press release11/6/2024, 12:34 PM

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma

Lytix Biopharma

Regulatory press release11/5/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Lytix Biopharma

Regulatory press release11/5/2024, 6:00 AM

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Lytix Biopharma

Regulatory press release11/1/2024, 6:04 AM

LYTIX: Financial calendar

Lytix Biopharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.